Literature DB >> 19506392

Long-term follow-up of GH-treated girls with Turner syndrome: metabolic consequences.

Ellen M N Bannink1, Roel L F van der Palen, Paul G H Mulder, Sabine M P F de Muinck Keizer-Schrama.   

Abstract

AIMS: To investigate the metabolic consequences of long-term GH treatment in young women with Turner syndrome (TS), several years after GH discontinuation.
METHODS: Follow-up study of a randomized GH dose-response trial, with 3 GH dosages (1.3, 2.0, and 2.7 mg/m(2)/day). Thirty-nine TS patients (20.0 +/- 2.1 years) participated 4.8 +/- 1.9 years after GH discontinuation. Mean GH treatment duration was 8.7 +/- 2.0 years. Fasting glucose, insulin, and serum lipids were measured.
RESULTS: Several years after GH discontinuation, insulin sensitivity remained lower, while beta-cell function and fasting insulin levels remained higher than before treatment. Only BMI influenced beta-cell function. Serum total cholesterol (TC), low-density lipoprotein and high-density lipoprotein (HDL) had further increased compared to 6 months after GH, resulting in higher TC, but also higher HDL levels compared to controls. The atherogenic index remained constant, but lower than controls.
CONCLUSIONS: Besides height, GH therapy in girls with TS has additional beneficial effects on serum lipids. Nearly 5 years after discontinuation of GH therapy the favorable effect of GH was still noticeable. The GH-induced decrease in insulin sensitivity, however, remained unchanged, possibly due to having TS. 2009 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19506392     DOI: 10.1159/000223419

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  3 in total

1.  Insulin resistance in adolescents with Turner syndrome is comparable to obese peers, but the overall metabolic risk is lower due to unknown mechanism.

Authors:  M Wojcik; D Janus; A Zygmunt-Gorska; J B Starzyk
Journal:  J Endocrinol Invest       Date:  2014-10-11       Impact factor: 4.256

2.  Brain-Derived Neurotropic Factor, Vascular Endothelial Growth Factor and Matrix Metalloproteinases as Markers of Metabolic Status in Non-Growth Hormone-Treated Girls With Turner Syndrome.

Authors:  Ewa Błaszczyk; Jakub Gawlik; Joanna Gieburowska; Agnieszka Tokarska; Małgorzata Kimsa-Furdzik; Grzegorz Hibner; Tomasz Francuz; Aneta Monika Gawlik
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-27       Impact factor: 5.555

3.  Recombinant growth hormone therapy in children with Turner Syndrome in Korea: a phase III Randomized Trial.

Authors:  Jinsup Kim; Min-Sun Kim; Byung-Kyu Suh; Cheol Woo Ko; Kee-Hyoung Lee; Han-Wook Yoo; Choong Ho Shin; Jin Soon Hwang; Ho-Seong Kim; Woo Yeong Chung; Chan Jong Kim; Heon-Seok Han; Dong-Kyu Jin
Journal:  BMC Endocr Disord       Date:  2021-12-10       Impact factor: 2.763

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.